The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer
Launched by THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY ·
Trial Information
Current as of September 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a helpful type of bacteria called Clostridium butyricum can reduce side effects in people receiving extra chemotherapy treatment after surgery for colorectal cancer, which is cancer in the colon or rectum. Chemotherapy can sometimes cause uncomfortable or harmful effects, and this study wants to see if taking this bacteria as a supplement can make treatment easier and safer.
The trial is open to adults of all genders who have colorectal cancer and are starting additional chemotherapy after surgery. While the study isn’t recruiting yet, eligible participants will be asked to take Clostridium butyricum during their chemotherapy and will be closely monitored for any side effects. This study is important because it may help improve the quality of life for people undergoing cancer treatment by reducing unwanted symptoms.
Gender
ALL
Eligibility criteria
About The Affiliated Hospital Of Qingdao University
The Affiliated Hospital of Qingdao University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise in various medical disciplines to enhance patient care and contribute to the global medical community. With a strong focus on translational medicine, the Affiliated Hospital collaborates with academic and industry partners to facilitate the development of novel therapies and medical interventions, ensuring adherence to the highest ethical standards and regulatory guidelines. Through its commitment to excellence in research and patient outcomes, the hospital aims to drive significant advancements in medical science and improve the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yanbing Zhou
Principal Investigator
The Affiliated Hospital of Qingdao University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported